fda warning letters glp-1 compounders september 2025 Drug Recalls and Warnings: Recalls for Compounded Semaglutide and Tirzepatide, Wegovy; Facility FDA Issues 30 Warning Letters

Description

doi: 10.1038/s41366-025-01859-6

Potential Side Effects of Semaglutide: As with any medication, Semaglutide may come with some side effects: Nausea, vomiting, and diarrhea: These are common, especially when first starting the treatment

Sign up for our newsletterStay ahead of development by receiving our newsletter on the latest sector knowledge.E-mail addressClearContinueI want to receive customized email newsletters from Watch Medier A/S, including information about our brands and group companies, conferences, courses, networking, competitions and digital services."n"nWith my consent, I also agree to the processing of my personal data and that information about my interaction with marketing messages (such as opening and reading) is collected using tracking pixels and similar technologies

Severe sepsis and cardiac arrhythmias

The bottom line: Our findings suggest that GLP-1RA and SGLT2i (and especially SGLT2i with the lowest number needed to treat (NNT) for nearly all study outcomes) may be the preferred glucose-lowering agents for cardiovascular risk reduction in patients at moderate risk for CVD, building on and consistent with existing RCT evidence in the high-risk population. This report highlights potential preference for GLP-1 drugs as a first-line treatment for Type 2 diabetes related to its cardioprotective effect